OPKO Health
Pharmaceuticals
Multinational United States Est. 2007
Team
1
51-200 employees
Confidence
66/100
News
16
articles
About
OPKO Health Inc is a multinational corporation that researches, develops, and produces a variety of pharmaceutical technologies. The company pursues diagnostics, genetic testing, cancer treatment, fertility, growth hormone deficiency, and other areas of pharmaceutical research. OPKO Israel encompasses two main entities: OPKO Biologics and FineTech Pharmaceutical. OPKO Biologics, previously known as Prolor Biotech, is a clinical-stage company that concentrates on creating long-acting versions of therapeutic proteins and peptide drugs. They employ advanced technologies such as CTP, reversible PEGylation, and native stabilizer proteins. On the other hand, FineTech is involved in the development of high-value Active Pharmaceutical Ingredients (APIs) and devises methods to bypass patents, facilitating faster commercial progress for its pharmaceutical clients.
Classification
Tags
biotechnologybiopharmaceuticaltherapeuticsfertilitymedical-devicesdrug-deliverylaboratoriesbiological-therapypharmaceuticalsdiagnosticsproteinsophthalmologypeptides
Funding & Events
Apr 2018
Exit Undisclosed
News (16)
Sep 18, 2025 · finance.yahoo.com
growth-positive
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
Product StagePartners
Sep 15, 2025 · finance.yahoo.com
growth-positive
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Product StagePartners
Jul 31, 2025 · finance.yahoo.com
growth-positive
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
Product StagePartners
Jul 23, 2025 · finance.yahoo.com
growth-positive
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
Partners
Jul 8, 2025 · finance.yahoo.com
growth-positive
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Product StagePartners
Jun 29, 2025 · finance.yahoo.com
growth-positive
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
Product StagePartners
Jun 25, 2025 · finance.yahoo.com
growth-positive
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Product StagePartners
Jun 24, 2025 · finance.yahoo.com
growth-positive
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
AcquisitionPartners
Sep 12, 2023 · investors.enterabio.com
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
Mar 8, 2020 · en.globes.co.il
growth-positive
Opko jumps on Covid-19 diagnostic lab announcement
CustomersInvestment
Oct 23, 2019 · en.globes.co.il
growth-negative
Opko Health seeks $100m in NYSE public offering
Investment
Feb 5, 2019 · en.globes.co.il
growth-negative
Opko to activate shelf prospectus to raise $200m
Investment
Apr 29, 2018 · www.calcalistech.com
growth-negative
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
Public Trading
Apr 10, 2018 · www.globes.co.il
growth-negative
Opko Health to delist from TASE
Public Trading
Apr 16, 2014 · www.globes.co.il
growth-positive
Opko turns Prolor into Israeli R&D, investment arm
Acquisition
Dec 21, 2011 · www.globes.co.il
growth-positive
OPKO Health buys FineTech Pharmaceutical for $27.5m
Acquisition
Details
Employees
51-200
Exact Count
59
Founded
2007
Crunchbase
opko-health
Locations
Ashlegan 15, Kiryat Gat, Israel
Miami, FL, USA
Links
Website
LinkedIn
Admin
Last Update
Oct 19, 2023
Verified by
Yamila Silbert
Missing
product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed
Team (1)
Laura Moschcovich
General Manager
Internal
Created by
Shmuel (Sam) Rausnitz (shmuel.rausnitz@sncentral.org)
Created
2016-06-20T00:00:00.000Z
Last editor
Maor Perlov (maor.perlov@sncentral.org)
Status
Public on NASDAQ on Nov, 1995;Public on TASE on Aug, 2013;
Recent activity
Maor Perlov · Manual · 2023-10-19 12:50:30.000000
Maor Perlov · Manual · 2023-10-19 12:56:29.000000
Maor Perlov · Manual · 2023-10-19 12:27:25.000000
Maor Perlov · Manual · 2023-10-19 12:56:48.000000
Maor Perlov · Manual · 2023-10-19 12:53:26.000000
Eran Levin · Automatic · 2024-12-05 14:20:15.000000
Eran Levin · Automatic · 2024-08-07 05:43:42.000000
Eran Levin · Automatic · 2024-12-05 14:52:29.000000
Maor Perlov · Manual · 2023-10-19 12:26:53.000000
Maor Perlov · Manual · 2023-10-19 12:50:30.000000